ArticleJournal of immunological methods2009
A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid.
Article in Journal of immunological methods, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Diagnostic Agreement in Subepidermal Blistering Diseases: Is ELISA Test Reliable as Direct Immunofluorescence? A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2026Pooled it
- IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review.Archives of dermatological research · 2018Pooled it
- Racial and ethnic disparities in T helper 2-mediated inflammatory skin disorders.Skin health and disease · 2026Review
- Shared Mechanistic Pathways in Bullous Pemphigoid, Chronic Spontaneous Urticaria, Prurigo Nodularis, and Chronic Prurigo of Unknown Origin: Implications for Targeted Therapies.American journal of clinical dermatology · 2026Review
- State-of-the-art diagnosis of autoimmune blistering diseases.Frontiers in immunology · 2024Review
- Advancing Treatment in Bullous Pemphigoid: A Comprehensive Review of Novel Therapeutic Targets and Approaches.Clinical reviews in allergy & immunology · 2023Review
- The Eotaxin-1/CCR3 Axis and Matrix Metalloproteinase-9 Are Critical in Anti-NC16A IgE-Induced Bullous Pemphigoid.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Elevated levels of sCD48 are inversely correlated with markers of disease activity in bullous pemphigoid.Experimental dermatology · 2023Article
- Bullous Pemphygoid and Novel Therapeutic Approaches.Biomedicines · 2022Review
- Controversies in Allergy: The Potential Role of Biologics as First-Line Therapy in Eosinophilic Disorders.The journal of allergy and clinical immunology. In practice · 2022Review
- Bullous pemphigoid-What do we know about the most recent therapies?Frontiers in medicine · 2022Review
- Bullous Pemphigoid and Other Pemphigoid Dermatoses.Medicina (Kaunas, Lithuania) · 2021Review
- IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients.Journal of the European Academy of Dermatology and Venereology : JEADV · 2021Article
- Resolution in bullous pemphigoid.Seminars in immunopathology · 2019Review
- Demographics and Autoantibody Profiles of Pemphigoid Patients with Underlying Neurologic Diseases.The Journal of investigative dermatology · 2019Article
- Serological Diagnosis of Autoimmune Bullous Skin Diseases.Frontiers in immunology · 2019Review
- Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.Frontiers in immunology · 2019Article
- The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.Frontiers in immunology · 2019Review
- Review
- Eosinophils Mediate Tissue Injury in the Autoimmune Skin Disease Bullous Pemphigoid.The Journal of investigative dermatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Bullous pemphigoid (BP) is a humoral autoimmune disease directed predominantly against the non-collagenous NC16A domain of the BP180 hemidesmosomal protein. Our laboratory has recently shown, using a mouse xenograft model, that passive transfer of IgE autoantibodies from BP sera induces a skin phenotype that recapitulates the early phases of the disease. Herein, we describe the development of a highly specific and sensitive ELISA to detect circulating IgE autoantibodies that recognize BP180-NC16A. Using this assay, we detected NC16A-specific IgE-class autoantibodies in 77% of BP sera. This frequency, which is significantly higher than reported previously, is comparable to that of anti-NC16A IgG autoantibody production. In 3 BP patients monitored over time, the circulating NC16A-specific levels of both IgE and IgG were associated with clinical disease activity; however, patient sera did not always contain high levels of both isotypes. In conclusion, our ELISA provides a highly sensitive and specific tool for the detection of BP180-specific IgE in patient sera. Furthermore, we report that the majority of BP sera contain both IgE and IgG class autoantibodies specific for NC16A and suggest that screening for both isotypes of autoantibodies may provide a better diagnostic value than IgG alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.